Clover Health Investments (CLOV) CEO Reynoso Sells $11K of Stock

Jamie Reynoso, the CEO of Medicare Advantage at Clover Health Investments, Corp. (NasdaqGS: CLOV), sold 2,360 shares of the company on June 17, 2026. The shares were sold at an average price of $4.78, totaling approximately $11,280.80. This transaction was planned under a Rule 10b5-1 trading plan.

Insider Buying and Selling at Clover Health Investments, Corp.

Jamie Reynoso wasn't the only insider selling shares recently. On June 16, 2026, Joseph Frank Oldakowski, VP of Finance and Controller, sold 12,102 shares at $4.86 each. On June 15, 2026, Reynoso also sold 6,350 shares at $4.61, and Karen Soares, Chief Legal Officer, sold 4,681 shares at the same price. These transactions were also part of planned sales.

Other Institutional Activity in Clover Health

Several institutional investors have been active in Clover Health recently. BlackRock, Inc. reduced its holdings by 440,347 shares, ending with 31,840,512 shares valued at approximately $56.0 million. Vanguard Capital Management LLC added 16,982,073 shares, now holding the same number of shares worth about $29.9 million. Geode Capital Management, LLC increased its position by 264,302 shares, holding 10,055,510 shares valued at $17.7 million. State Street Corp added 239,706 shares, resulting in 9,559,889 shares valued at $16.8 million. Charles Schwab Investment Management Inc grew its position by 609,571 shares, now holding 5,300,475 shares worth about $9.3 million.

Clover Health Investments, Corp. Stock Up 4.4%

Shares of Clover Health (NasdaqGS: CLOV) are trading near $4.80. The company has a market capitalization of approximately $2.53 billion and a forward P/E ratio of 48.0. With a beta of 2.484, the stock has experienced significant volatility. Over the past 52 weeks, the stock has traded as low as $1.58 and as high as $5.18. Its 50-day moving average is $3.23, while the 200-day moving average is $2.70. The current and quick ratios stand at 1.331 and 1.207, respectively.

Recent Earnings

Clover Health reported revenue of about $2.21 billion, growing by 62%. However, the company recorded a net margin of -2.58% and a return on equity of -16.86%, indicating it is not yet profitable. The next earnings report is expected on August 4, 2026.

Analysts Set New Price Targets

On June 11, 2026, UBS maintained a 'hold' rating on Clover Health with a price target of $4.75. Earlier, on June 4, 2026, Canaccord Genuity maintained its 'buy' rating with a target price of $4.20. The consensus among analysts is a 'buy' rating, with an average target price of $4.15 based on three analyst opinions.

About Clover Health Investments

Clover Health Investments, Corp. provides Medicare Advantage plans in the U.S., offering preferred provider organization and health maintenance organization plans to eligible individuals. It also operates Clover Assistant, a software platform for managing chronic diseases. Founded in 2014, the company is headquartered in Wilmington, Delaware, and led by CEO Andrew Toy. Clover Health employs around 724 people.

Bottom Line

Jamie Reynoso's planned sale of shares reflects routine insider activity at Clover Health. Investors follow such insider transactions to gauge confidence in the company's future. Clover Health continues to show growth in revenue, though profitability remains a challenge. Analyst ratings suggest cautious optimism, with a consensus 'buy' rating despite the company's current financial hurdles.